Have questions? Visit https://www.reddit.com/r/SNPedia

rs2046934

From SNPedia

Orientationminus
Stabilizedminus
Make rs2046934(C;C)
Make rs2046934(C;T)
Make rs2046934(T;T)
ReferenceGRCh38 38.1/141
Chromosome3
Position151339854
GeneMED12L, P2RY12
is asnp
is mentioned by
dbSNPrs2046934
ebirs2046934
HLIrs2046934
Exacrs2046934
Varsomers2046934
Maprs2046934
PheGenIrs2046934
hapmaprs2046934
1000 genomesrs2046934
hgdprs2046934
ensemblrs2046934
gopubmedrs2046934
geneviewrs2046934
scholarrs2046934
googlers2046934
pharmgkbrs2046934
gwascentralrs2046934
openSNPrs2046934
23andMers2046934
23andMe allrs2046934
SNP Nexus

SNPshotrs2046934
SNPdbers2046934
MSV3drs2046934
GWAS Ctlgrs2046934
GMAF0.1529
Max Magnitude
? (C;C) (C;T) (T;T) 28

[PMID 17707382] rs10935838, rs2046934, rs5853517, and rs6809699 venous thromboembolism lower risk of incident DVT/PE as compared to the reference haplotype H1 (odds ratio=0.50, 95% CI=0.27-0.93, p=0.028)


[PMID 19786296] Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction





[PMID 18213371OA-icon.png] The P2Y 13 Met-158-Thr polymorphism, which is in linkage disequilibrium with the P2Y 12 locus, is not associated with acute myocardial infarction.


[PMID 20126830] The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.


GET Evidence
rs2046934
aa_change
aa_change_short
impact pharmacogenetic
qualified_impact Insufficiently evaluated pharmacogenetic
overall_frequency 0.801587
summary



[PMID 26083990] Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects


[PMID 26870959] Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.